Dasabuvir is an antiviral drug used for the treatment of hepatitis C virus (HCV) infection. As a Non-Nucleoside NS5B Polymerase Inhibitor, dasabuvir functions by inhibiting Nonstructural Protein 5B (NS5B), an RNA-dependent RNA polymerase required for viral replication of Hepatitis C Virus. By binding to NS5b outside of the active site of the enzyme, dasabuvir induces a conformational change thereby preventing further elongation of the nascent viral genome. A limitation of binding outside of the active site is that these binding sites are poorly preserved across the viral genotypes. This results in a limited potential for cross-genotypic activity and increased potential for development of resistance. Dasabuvir is therefore limited to ...
Read More treating genotypes 1a and 1b, and must be used in combination with other antiviral products. Dasabuvir is currently approved for use in the management of Hepatitis C infection in combination with ombitasvir, paritaprevir, and ritonavir as the combination product Viekira Pak.